Background and Purpose-Because of the limitation in treatment window of the r-tPA (recombinant tissue-type plasminogen activator), the development of delayed treatment for stroke is needed. In this study, we examined the efficacy of delayed poststroke treatment (post 3-8 days) of the sonic hedgehog pathway agonist on functional recovery and the underlying mechanisms. Methods-We evaluated functional recovery at 1 month after stroke using locomotion analysis and Barnes maze test for cognitive function. We used a genetically inducible neural stem cell-specific reporter mouse line (nestin-CreERT2-R26R-YFP) to label and track their proliferation, survival, and differentiation in ischemic brain. Brain tissue damage, angiogenesis, and cerebral blood flow recovery was evaluated using magnetic resonance imaging techniques and immunostaining. Results-Our results show that delayed treatment of sonic hedgehog pathway agonist in stroke mice results in enhanced functional recovery both in locomotor function and in cognitive function at 1 month after stroke. Furthermore, using the Nestincre-ERT2-YFP mice, we showed that poststroke sonic hedgehog pathway agonist treatment increased surviving newly born cells derived from both subventricular zone and subgranular zone neural stem cells, total surviving DCX+ (Doublecortin) neuroblast cells, and neurons (NeuN+/YFP+) in the ischemic brain. Sonic hedgehog pathway agonist treatment also improved the brain tissue repair in ischemic region supported by our T2-weighted magnetic resonance imaging, cerebral blood flow map by arterial spin labeling, and immunohistochemistry (α-smooth muscle actin and CD31 immunostaining). Conclusions-These data confirm an important role for the hedgehog pathway in poststroke brain repair and functional recovery, suggesting a prolonged treatment window for potential treatment strategy to modulate sonic hedgehog pathway after stroke. 
B
ecause of the limitation in treatment window of the r-tPA (recombinant tissue-type plasminogen activator), only a small percentage of patients are treated in the acute window (4.5 hours) after stroke onset. 1 Therefore, therapeutic strategies targeting the subacute and chronic stages of the disease are needed. Recent studies using genetic ablation systems to specifically diminish neuroprogenitor cells or immature neuroblasts in stroke mice demonstrate the contribution of adult neural stem cells (NSCs) and their progeny in the functional recovery in stroke. 2, 3 However, the spontaneous brain repair process is limited and does not lead to full recovery after stroke. 4 One of the major challenges is the survival of newly generated cells after stroke. It has been estimated that 80% of newly born cells originating from the adult stem cell niche subventricular zone (SVZ) die during the first 2 weeks after their formation in stroke animals. 5 Therefore, enhancing the survival of newly born cells is an important priority for enhancing neurogenesis after stroke. Potential therapeutic treatments such as stem cell transplantation have shown efficacy in the subacute and chronic stroke stages in animal models, potentially through facilitating endogenous repair mechanisms such as neurogenesis and angiogenesis. 6, 7 Sonic hedgehog (shh) signaling play important roles in the self-renewal, proliferation, and migration of NSCs. 8, 9 We and others have shown the beneficial effects of shh activation in brain injury animal models, including stroke. [10] [11] [12] In a previous study, we have shown that the shh gene is upregulated in multiple cell types after stroke and deletion of shh signaling in NSCs lead to compromised functional recovery in stroke mice. In the same study, we found that poststroke shh agonist (SAG) treatment leads to enhanced functional recovery in the subacute phase of stroke (poststroke day 7) in a distal middle cerebral artery occlusion (MCAo) model. 12 However, whether the SAG molecule leads to long-term functional recovery and its effects on neurogenesis and the survival of newly generated cells in the transient filament MCAo model is unknown. In this study, we evaluated the efficacy of delayed poststroke treatment (poststroke day 3 to 8) of SAG in long-term functional recovery after MCAo and brain tissue repair and cerebral blood flow (CBF) recovery using magnetic resonance imaging (MRI) technique. In addition, to specifically examine the effects and mechanisms of shh-signaling activation on NSCs in the SVZ and subgranular zone (SGZ) in stroke mice, we used a genetically inducible NSC-specific reporter mouse line (nestin-CreERT2-R26R-YFP) to label and track their proliferation, differentiation, and survival.
Materials and Methods

Animals
All animal protocols were conducted under National Institutes Health (NIH) Guidelines using the NIH handbook Animals in Research and were approved by the Institutional Animal Care and Use Committee (Case Western Reserve University). Male C57BL/6 mice (10-12 weeks old) were used in this study. To evaluate neurogenesis in stroke mice, the nestin-CreERT2-R26R-YFP strain was used in this study.
Chemical
SAG was purchased from Cayman Chemical Company (Ann Arbor, MI). SAG is dissolved in 0.5% Cellulose Tween-80 solution at a final concentration of 1 mg/mL. Animals received SAG at the dosage of 10 mg•kg −1 •d −1 through gavage feeding from poststroke day 3 to 8. Activity of each batch of SAG was confirmed in laboratory by its effects on stimulating proliferation of in vitro cultured SVZ NSCs neurosphere culture.
Study Design and Timeline
A total of 138 mice were used in this study (102 C57BL/6 male mice and 36 nestin-CreERT2-R26R-YFP male mice). Male mice were used in this study to reduce experimental variability in stroke. The animals were subjected to the following experiments: 28 mice were subjected to MCAo and received either vehicle or SAG treatment from poststroke day 3 to 8. Mice were subject to locomotion behavioral functional test before MCAo and at 3, 7, 21, and 28 days after MCAo. Additional 36 mice were subjected to MCAo and received either vehicle or SAG treatment (poststroke day 3-8) and were evaluated for Barnes maze test to evaluate memory and learning at 30 days poststroke. Eighteen mice from the Barnes maze test group were subjected to MRI study on poststroke days 2 and 30 to evaluate ischemic damage and CBF. To evaluate the effect of SAG treatment on Barnes maze performance on control mice, mice received SAG or vehicle treatment (10 mg/kg for 6 days, n=9 for each group) without surgery and were subjected to Barnes maze test 21 days later. To evaluate the proliferation of SVZ and SGZ cells, Bromodeoxyuridine (BrdU) pulse labeling was performed on poststroke day 6 after either vehicle or SAG treatment, and brains were harvested 24 hours later to quantify BrdU+, PCNA+ (proliferating cell nuclear antigen), or Ki67+ cells (20 mice). To evaluate neurogenesis and long-term survival of NSC progeny, 20 nestin-CreERT2-R26R-YFP mice were treated with tamoxifen to induce yellow fluorescent protein (YFP) labeling of SVZ and SGZ NSCs and treated with either vehicle or SAG (poststroke day 3 to 8). YFP+, DCX+, or NeuN+ cells were analyzed by unbiased stereological method at 30 days post-stroke. Mice from the MRI study and the nestin-CreERT2-R26R-YFP were combined to analyze the DCX+ cells and angiogenesis as well. To examine gene expression in SVZ NSCs, additional 16 nestin-CreERT2-R26R-YFP mice were subjected to MCAo and SAG or vehicle treatment (poststroke day 3 to 8), and SVZ tissue microdissected using methods described in a previous study 13 for quantitative real-time polymerase chain reaction. To evaluate angiogenesis by histochemistry, brain sections from poststroke day 30 mice were subjected to immunostaining using 2 different markers, α-smooth muscle actin and CD31, and quantitatively analyzed as described in detail in the online-only Data Supplement.
All the experimental groups are randomized, and all outcome analyses were performed by independent study team members blinded to the treatment condition. Details on experimental timeline, randomization and blinding of groups, animal numbers for each experiment, and survival rate/exclusions because of death are included in the online-only Data Supplement. Details on each assay are also included in the online-only Data Supplement.
Statistics
Results are expressed by mean±SEM of the indicated number of experiments. Statistical analysis was performed using Student t test and 1-or 2-way ANOVA, as appropriate, with Student-NewmanKeuls post hoc tests or Bonferroni post hoc tests for repeated behavioral measurements. A P value ≤0.05 was considered significant.
Results
Poststroke shh Agonist (SAG) Treatment (Poststroke Day 3-8) After MCAo Enhanced the Locomotor Behavioral Recovery and Cognitive Function at 1 Month After Stroke
To examine whether poststroke SAG treatment lead to longterm improvement in behavioral function in the tMCAo model (transient middle cerebral artery occlusion), we tested the vehicle-or SAG-treated mice with behavioral tests that evaluated either locomotor or cognitive function. There is no difference in any of the parameters measured in the 2 groups before or at poststroke day 3 after MCAo ( Table I in Table II in the online-only Data Supplement). SAG treatment administered on poststroke days 3 and 6 showed a trend of improvement on multiple parameters starting on poststroke day 7, which became highly significant in all the parameters measured at 3 weeks poststroke but plateaued at 4 weeks after stroke, which still were significantly improved compared with vehicle-treated mice in multiple parameters including horizontal activity, distance traveled, number of movements, and movement time (Figure 1 ). At the last time point (poststroke day 28), the vertical activities between the 2 groups were no longer statistically significant.
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To determine whether poststroke SAG treatment affects stroke-induced functional deficits in learning and memory, we also evaluated cognitive function in control or poststroke SAGtreated mice. To minimize the interference of other behavioral tests on cognitive function test, a separate group of mice was used in this test. Four groups of mice were tested at 21 days after SAG or vehicle treatment (control or stroke+vehicle or SAG). Two variables (surgery and treatment) were used to analyze changes in behaviors using a 2-way ANOVA. Results show that stroke-induced deficits in learning and memory in vehicletreated mice ( Figure 1B ; P=0.008 for time spent and P=0.019 for error trials ANOVA, post hoc Student-Newman-Keuls test, n=9 for control+vehicle and n=12 for stroke+vehicle). In control mice, SAG or vehicle treatment shows no difference (n=9 for each group), suggesting that SAG does not promote memory in naive young animals. For stroke mice, MRI at 2 days after MCAo showed that there was no difference in infarct size between these 2 groups of mice (33.95±5.79% hemisphere for vehicle and 32.64+5.83% hemisphere for SAG-treated mice) before the treatment started. However, at 30 days after stroke, stroke mice that received SAG treatment spent significantly less time to find the escape hole compared with vehicle-treated stroke mice ( Figure 1B ; P=0.006, ANOVA, post hoc StudentNewman-Keuls test; n=12 for stroke+vehicle and n=14 for stroke+SAG), which is not significantly different from control mice (P=0.416, control+SAG versus stroke+SAG). In addition, SAG-treated mice also took less error trials to find the escape hole ( Figure 1B ; P=0.003, stroke+vehicle versus stroke+SAG), which is not significantly different from control mice (P=0.830, control+SAG versus stroke+SAG). These data indicate that SAG treatment restored cognitive function in stroke mice.
Poststroke shh Agonist (SAG) Treatment (Poststroke Day 3-8) After MCAo Increased the Survival but Not Proliferation of SVZ and SGZ NSCs Progeny and Total Neuroblast Cells at 1 Month After Stroke
To examine whether SAG poststroke treatment improved behavioral functions through modulation of proliferation or survival of NSCs and their progeny, we used a NSC-specific inducible cell-labeling system as previously reported by us and others. 12, 14, 15 Using this mouse line, we labeled NSCs before MCAo and tracked their survival and differentiation into neuronal phenotype at 30 days after MCAo in vehicleor SAG-treated mice using unbiased stereological counting of YFP-and DCX-positive cells. On contralateral side, there is no migration of YFP-or DCX-positive cells into the striatal or cortical region in vehicle-or SAG-treated groups. On the ipsilateral side of the brain, there are significant expansion and migration of YFP+ cells into striatal and some cortical region from SVZ to the ischemic core (Figure 2A) . Importantly, SAG treatment resulted in increased YFP+ cells in striatal and cortical area on ipsilateral side (Figure 2B and 2C ; Student t test, t=2.469; P=0.03; n=7 for each group). In addition, total DCX+ cells migrated into the striatal and cortical area were also increased in SAG-treated mice (Figure 2B and 2C ; Student t test, t=2.368; P=0.026; n=13 for each group). The percentage of YFP+ cells that were also DCX+ does not differ between vehicle-and SAG-treated mice (Figure 2B and 2C ; P=0.96, Student t test), suggesting that poststroke SAG treatment increased the total surviving YFP+/DCX+ cells at 30 days post-stroke without affecting the neuronal differentiation percentage. Similarly, using unbiased stereological quantification, we also observed increased total number of YFP+/NeuN+ cells in striatal and cortical area of the ipsilateral side in SAGtreated mice compared with vehicle-treated mice ( Figure IA in the online-only Data Supplement; P<0.05, Student t test).
To determine whether poststroke SAG increased the total number of YFP+ cells at 30 days by enhancing the proliferation of NSCs or the survival of newly born cells that are progeny of the SVZ NSCs, we treated mice with either vehicle or SAG (poststroke day 3-7) and injected BrdU on poststroke day 6 to evaluate proliferating cell numbers by both BrdU labeling and PCNA labeling. Ventral SVZ NSCs differ from dorsal SVZ NSCs in their expression of smoothened (Smo) receptor and might respond to SAG differentially. 16 We quantified proliferating cells in vehicle-or SAG-treated mice in both dorsal and ventral SVZ. Our results indicate that ipsilateral side ventral SVZ showed increased proliferation compared with contralateral side SVZ in both vehicle-and SAG-treated mice (Figure 3, for SAG-treated mice measured by either BrdU+ cells (Figure 3 (Figure 3 ). To further confirm that this in vivo SAG treatment regimen indeed increase shh signaling in NSCs at the SVZ, we harvested SVZ tissue in nestin-Cre-ERT2-R26R-YFP using technique described previously 13 and analyzed gene expression in both contralateral and ipsilateral SVZ in vehicle-or SAG-treated stroke mice. Our results show no significant difference in 2 housekeeping genes (Hmbs and Hprt1) in any groups but a significant increase of smoothened Multiple processes have been implicated to be important in the survival of adult born neuronal lineage cells, especially under pathological condition. Angiogenesis has been coupled with neurogenesis and regulate the proliferation, survival, and migration of newly born cells. [17] [18] [19] [20] Therefore, we examined the tissue damage and CBF at day 2 and day 30 after MCAo in vehicle-and SAG-treated mice by MRI. T 2 -weighted images of SAG-and vehicle-treated mice on day 2 and day 30 showed that ischemic edema volume in SAG-treated mice was similar to vehicle-treated mice at both day 2 and day 30. At day 2, ischemic region in both groups showed significantly higher T 2 signaling than the contralateral hemisphere, and there was no difference in either edema volume or T 2 relaxation time between the 2 groups ( Figure 5 ; P>0.05, ANOVA). At day 30, the volume of T 2 -elevated areas had decreased in both groups, and there was no significant difference in the T 2 -elevated volume between the 2 groups ( Figure 5 ; P>0.05, ANOVA). Vehicle-treated mice showed further increase in T 2 relaxation time in the ischemic region as compared with day 2, possibly implying irreversible neuronal damage. 7 In contrast, SAG-treated mice showed decreased T 2 in the ischemic area, reaching a similar level as the contralateral brain tissue (Figure 5 ; P=0.002, vehicle versus SAG at day 30, ANOVA; n=7). In addition, SAG-treated mice also showed increased CBF in the perilesion and lesion core areas (T2-elevated area) at day 30 compared with vehicle-treated mice (Figure 6 ; P=0.021, vehicle versus SAG at day 30, ANOVA; n=7), indicating enhanced angiogenesis and blood flow supply. Consistent with MRI and CBF imaging, we found that the number of α-SMA-positive blood vessels was significantly enhanced by SAG treatment (Figure 6A ; P<0.001, Student t test; n=8-9) in the ischemic region. In addition, CD31 immunostaining also confirms higher density of CD31-positive blood vessels in the peri-infarct area of SAG-treated mice compared with vehicle-treated mice ( Figure 6B ; P=0.034, Student t test, n=8). These data consistently suggest that poststroke SAG treatment increased vascularization in the lesion side striatum and cortex, a mechanism that might contribute to the increased survival of NSC progeny.
Discussion
The shh-signaling pathway has been reported to regulate SGZ proliferation after hippocampal ischemia because inhibition of shh pathway by antagonist Cyclopamine reduces ischemiainduced proliferation in the SGZ. 21 However, it is unknown whether stimulation of shh signaling would further potentiate ischemia-induced proliferation in the SGZ. We and others have reported that shh pathway is upregulated in multiple cell types after stroke, and we have shown that poststroke treatment of a shh agonist (poststroke day 3) in distal MCAo leads to functional improvement in the subacute phase after stroke. 12 An independent study also reported that treatment of a different shh pathway agonist (Purmorphamine) administered at early poststroke stage (6 hours) leads to decreased neuronal damage, blood brain barrier integrity, and reduced reactive astrogliosis. 11 However, because the 6-hour treatment after stroke does not distinguish neuroprotection from neuroregeneration mechanisms, it is not clear whether delayed activation of shh signaling would alone lead to enhanced brain repair.
Our data showed that delayed treatment of SAG (poststroke day 3-8) significantly improved locomotion function in multiple parameters and cognitive function in memory and learning in Barnes maze test at 1 month after stroke. To specifically track and fate map SVZ and SGZ NSCs and quantify their differentiation and survival under SAG treatment, we used Nestincre-ERT2-YFP mice to induce the expression of YFP reporter gene in SVZ and SGZ NSCs in adult mice before MCAo onset. Although SVZ-derived newborn cells have been shown to differentiate into NeuN-positive cells, only few new neurons survive in postischemic brain. 5 Similarly, SGZ NSCs also respond to ischemia by increased proliferation; however, the survival rate of the newly born cells in ischemic animals is lower than that of nonstroke animal at 1 month later. 22 In this study, using the Nestincre-ERT2-YFP mice in combination of analysis of proliferating cells in SVZ and SGZ by both BrdU labeling and endogenous proliferating markers PCNA or ki67, our data suggest that in vivo poststroke SAG treatment at this dosage enhances the survival of newly born cells rather than further improving the proliferation. Whether there is a causal relationship between hippocampal neurogenesis and the recovery of poststroke cognitive function in this particular MCAo model warrants further investigation in the future, possibly using genetic tagging and ablation techniques that will specifically distinguish hippocampal neurogenesis.
In both the SVZ neurogenic niche and the ischemic area, angiogenesis and neurogenesis has been shown to be closely coupled. Using MRI imaging, we found that delayed SAG treatment does not affect the volume of T 2 -elevated area at 30 days post-stroke. However, SAG-treated mice showed decreased T 2 values in the ischemic area, reaching a similar level as the contralateral brain tissue, whereas vehicle-treated mice showed further elevated T2, possibly implying longterm irreversible tissue damage. 23 Consistently, SAG treatment also lead to enhanced CBF reperfusion in the ischemic area, confirmed both by MRI and by immunostaining, indicating enhanced angiogenesis in ischemic area and enhanced functional reperfusion. This could be one of the mechanisms for observed enhanced survival of newly born cells. Shh signaling has been reported to enhance angiogenesis, through regulation of vascular endothelial growth factor, stromal cellderived factor-1, and angiopoietins. 24, 25 In contrast to shh peptide, small molecule of shh pathway activator has the advantage of stability and ease of delivery. This SAG has been shown to readily cross blood brain barrier and induce shh pathway activation in vivo through regulation of smoothened function. [26] [27] [28] [29] Recently, this shh-signaling pathway agonist (SAG) has also been reported to correct anatomic and behavioral deficits in a mouse Down syndrome model by a single injection at birth (20 mg/kg dosage), 30 also suggesting that temporary activation of shh pathway could lead to longterm modulation brain development and function. In summary, our data show that delayed poststroke treatment of systemic SAG administration lead to enhanced survival of adult NSCs in both SVZ and SGZ, enhanced angiogenesis, and CBF reperfusion in ischemic brain and improved long-term functional recovery in stroke mice. These observations further indicate that modulating shh pathway might be a possible treatment strategy to improve functional recovery after stroke.
Sources of Funding
This study is funded by the American Heart Association and National Institutes of Health grant (R01NS091213).
